Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of ...
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...
The Nassau Guardian22 小时
Chronic kidney disease projected to be 5th leading cause of death in five years
With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is ...
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea ...
Transformative new ‘TTT’ treatment could cure ‘silent killer’ in half a million ...
HALF a million Brits with deadly high blood pressure could be cured by a transformative new treatment. Doctors from the UK ...
Everyday Health4 天
What Is Addison’s Disease?
Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...
Verywell Health5 天
7 Common Uses of Spironolactone
Spironolactone is a diuretic (water pill) commonly used to treat heart failure and high blood pressure, but it can also be used for other conditions.